Innovent to Participate and Present at the 43rd Annual J.P. Morgan Healthcare Conference
Innovent Biologics (HKEX: 01801), a global biopharmaceutical company, announces its participation in the 43rd Annual J.P. Morgan Healthcare Conference from January 13-16, 2025, in San Francisco. Dr. De-Chao Michael Yu, the company's Founder, Chairman and CEO, will deliver a presentation on January 16 at 8:30 a.m. PST, covering business updates, strategic priorities, and future outlook.
The conference, recognized as the industry's largest healthcare investment symposium, will host over 8,000 investors and representatives from 550 global healthcare companies. Dr. Yu will also participate in a panel discussion on 'China Biopharma Industry Global Expansion Strategy' on January 15 at 2:15 p.m. PST.
Innovent, which develops and commercializes medicines for oncology, cardiovascular, metabolic, autoimmune, ophthalmology, and other major diseases, will provide live audio webcasts and presentation slides through their website.
Innovent Biologics (HKEX: 01801), un'azienda biopharma globale, annuncia la sua partecipazione al 43掳 Annual J.P. Morgan Healthcare Conference che si terr脿 dal 13 al 16 gennaio 2025 a San Francisco. Il Dr. De-Chao Michael Yu, fondatore, presidente e CEO dell'azienda, presenter脿 il 16 gennaio alle 8:30 ora PST, trattando aggiornamenti aziendali, priorit脿 strategiche e prospettive future.
La conferenza, riconosciuta come il pi霉 grande simposio di investimento in sanit脿 del settore, ospiter脿 oltre 8.000 investitori e rappresentanti di 550 aziende sanitarie globali. Il Dr. Yu parteciper脿 anche a una discussione di panel sulla 'Strategia di Espansione Globale dell'Industria Biopharma Cinese' il 15 gennaio alle 14:15 ora PST.
Innovent, che sviluppa e commercializza farmaci per oncologia, cardiovascolare, metabolica, autoimmune, oftalmologia e altre malattie principali, fornir脿 webcast audio dal vivo e diapositive delle presentazioni attraverso il loro sito web.
Innovent Biologics (HKEX: 01801), una compa帽铆a biofarmac茅utica global, anuncia su participaci贸n en la 43陋 Conferencia Anual de Salud J.P. Morgan del 13 al 16 de enero de 2025 en San Francisco. El Dr. De-Chao Michael Yu, fundador, presidente y CEO de la compa帽铆a, realizar谩 una presentaci贸n el 16 de enero a las 8:30 a.m. PST, abarcando actualizaciones comerciales, prioridades estrat茅gicas y perspectivas futuras.
La conferencia, reconocida como el simposio de inversi贸n en salud m谩s grande de la industria, albergar谩 a m谩s de 8,000 inversores y representantes de 550 empresas globales de salud. El Dr. Yu tambi茅n participar谩 en una discusi贸n de panel sobre la 'Estrategia de Expansi贸n Global de la Industria Biopharma de China' el 15 de enero a las 2:15 p.m. PST.
Innovent, que desarrolla y comercializa medicamentos para oncolog铆a, cardiovascular, metab贸lica, autoinmunitaria, oftalmolog铆a y otras enfermedades importantes, proporcionar谩 transmisiones de audio en vivo y diapositivas de las presentaciones a trav茅s de su sitio web.
Innovent Biologics (HKEX: 01801), 旮�搿滊矊 靸濍鞚橃暯頀� 須岇偓,電� 2025雲� 1鞗� 13鞚茧秬韯� 16鞚缄箤歆� 靸岉攧霝�鞁滌姢旖旍棎靹� 鞐措Μ電� 鞝�43須� JP氇贝 項姢旒�鞏� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 彀诫鞛愳澊鞛� 須岇灔, CEO鞚� Dr. De-Chao Michael Yu電� 1鞗� 16鞚� 鞓れ爠 8鞁� 30攵� PST鞐� 牍勳雼堨姢 鞐呺嵃鞚错姼, 鞝勲灥鞝� 鞖办劆靷暛 氚� 氙鸽灅 鞝勲鞚� 雼る， 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
鞚� 旎嵓霟办姢電� 鞐呹硠鞐愳劀 臧�鞛� 韥� 項姢旒�鞏� 韴瀽 鞁彫歆�鞐勳溂搿�, 8,000氇� 鞚挫儊鞚� 韴瀽鞛愳檧 550臧滌潣 鞝� 靹戈硠 項姢旒�鞏� 旮办梾鞚� 雽�響滊摛鞚� 彀胳劃頃� 鞓堨爼鞛呺媹雼�. Dr. Yu電� 霕愴暅 1鞗� 15鞚� 鞓ろ泟 2鞁� 15攵� PST鞐� '欷戧淡 氚旍澊鞓れ牅鞎� 靷办梾鞚� 旮�搿滊矊 頇曥灔 鞝勲灥'鞐� 雽�頃� 韺剱 韱犽鞐� 彀胳棳頃� 瓴冹瀰雼堧嫟.
Innovent電� 膦呾枒頃�, 鞁槇甏�, 雽�靷�, 鞛愱皜 氅挫棴, 鞎堦臣 氚� 旮绊儉 欤检殧 歆堧硲鞚� 鞙勴暅 鞚橃暯頀� 臧滊皽 氚� 靸侅梾頇旊ゼ 歆勴枆頃橂┌, 鞗轨偓鞚错姼毳� 韱淀暣 霛检澊敫� 鞓る敂鞓� 鞗轨簮鞀ろ姼 氚� 頂勲爤鞝犿厡鞚挫厴 鞀澕鞚措摐毳� 鞝滉车頃� 瓴冹瀰雼堧嫟.
Innovent Biologics (HKEX: 01801), une entreprise biopharmaceutique mondiale, annonce sa participation 脿 la 43e Conf茅rence Annuelle du J.P. Morgan Healthcare du 13 au 16 janvier 2025 脿 San Francisco. Le Dr. De-Chao Michael Yu, fondateur, pr茅sident et PDG de la soci茅t茅, fera une pr茅sentation le 16 janvier 脿 8h30 PST, abordant les mises 脿 jour commerciales, les priorit茅s strat茅giques et les perspectives d'avenir.
La conf茅rence, reconnue comme le plus grand symposium d'investissement dans le secteur de la sant茅, rassemblera plus de 8 000 investisseurs et repr茅sentants de 550 entreprises de sant茅 脿 l'茅chelle mondiale. Le Dr. Yu participera 茅galement 脿 une discussion en panel sur 'La Strat茅gie d'Expansion Globale de l'Industrie Biopharma Chinoise' le 15 janvier 脿 14h15 PST.
Innovent, qui d茅veloppe et commercialise des m茅dicaments pour l'oncologie, les maladies cardiovasculaires, m茅taboliques, auto-immunes, ophtalmologiques et d'autres maladies majeures, fournira des webdiffusions audio en direct et des diapositives de pr茅sentation sur leur site web.
Innovent Biologics (HKEX: 01801), ein globales biopharmazeutisches Unternehmen, k眉ndigt seine Teilnahme an der 43. J.P. Morgan Healthcare-Konferenz vom 13. bis 16. Januar 2025 in San Francisco an. Dr. De-Chao Michael Yu, der Gr眉nder, Vorsitzende und CEO des Unternehmens, wird am 16. Januar um 8:30 Uhr PST eine Pr盲sentation halten, die sich mit Unternehmensupdates, strategischen Priorit盲ten und zuk眉nftigen Aussichten befasst.
Die Konferenz, die als das gr枚脽te Investitionssymposium im Gesundheitswesen der Branche anerkannt ist, wird 眉ber 8.000 Investoren und Vertreter von 550 globalen Gesundheitsunternehmen versammeln. Dr. Yu wird au脽erdem am 15. Januar um 14:15 Uhr PST an einer Podiumsdiskussion 眉ber die 'Globale Expansionsstrategie der chinesischen Biopharma-Industrie' teilnehmen.
Innovent, das Arzneimittel f眉r Onkologie, Herz-Kreislauf-Erkrankungen, Stoffwechsel, Autoimmunerkrankungen, Augenheilkunde und andere schwerwiegende Erkrankungen entwickelt und kommerzialisiert, wird Live-Audio-Webcasts und Pr盲sentationsfolien 眉ber ihre Webseite bereitstellen.
- None.
- None.
SAN FRANCISCO听and
The 43rd J.P. Morgan Annual Healthcare Conference will be held from January 13 to 16, 2025 in
Company Presentation
Time:听Thursday, January 16, at 08:30 a.m. PST
Speaker: Dr. De-Chao Michael Yu, the Founder, Chairman and CEO of Innovent
Live audio webcast:
Presentation slides锛�听
* will be available on the Innovent website - Investors & Media section after the live presentation
Panel Discussion
Time:听Wednesday, January 15, at 2:15 p.m. PST
Theme: China Biopharma Industry Global Expansion Strategy
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 13 products in the market. It has 4 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.
Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit , or follow Innovent on Facebook and LinkedIn.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to听Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
View original content:
SOURCE Innovent Biologics
FAQ
When and where will Innovent present at the 2025 J.P. Morgan Healthcare Conference?
What topics will be covered in Innovent's presentation at the 2025 JPM Healthcare Conference?
How can investors access Innovent's JPM Healthcare Conference presentation?
What panel discussion will Innovent participate in at the 2025 JPM Healthcare Conference?
What therapeutic areas does Innovent focus on?
